Responsiveness to cholinesterase inhibitors in Alzheimer's disease: A possible role for the 192 Q/R polymorphism of the PON-1 gene

Neuroscience Letters

Volumn 382, Issue 3, 2005, Pages 338-341

  Pola, Roberto ^a   Flex, Andrea ^a   Ciaburri, Michele ^a   Rovella, Emilio ^a   Valiani, Angela ^a   Reali, Giada ^a   Silveri, Maria C ^a   Bernabei, Roberto ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Gene polymorphism; Paraoxonase 1

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTERASE; RIVASTIGMINE; UNCLASSIFIED DRUG;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; ARYLDIALKYLPHOSPHATASE; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; MALE; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 19544392168     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2005.03.027     Document Type: Article

References (20)

1. S. Adkins, K.N. Gan, M. Mody, and B. La Du Molecular basis of the polymorphic forms of human serum paraoxonase/arylesterase: glutamine for arginine at position 191, for the respective A or B allozymes Am. J. Hum. Genet. 52 1993 598 608
2. J. Aerssens, P. Raeymaekers, S. Lilienfeld, H. Geerts, F. Konings, and W. Parys APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease Dement. Geriatr. Cogn. Disord. 12 2001 69 77
3. O. Almkvist, V. Jelic, K. Amberla, E. Hellstrom-Lindhal, L. Meurling, and A. Nordberg Responder characteristics to a single-dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients Dement. Geriatr. Cogn. Disord. 12 2001 22 32
4. T. Babic, D.M. Lakusic, J. Sertic, M. Petrovecki, and A. Stavljenic-Rukavina ApoE genotyping and response to galanthamine in Alzheimer's disease - a real life retrospective study Coll. Antropol. 28 2004 199 204
5. B. Borroni, C. Pettenati, T. Bordonali, N. Akkawi, M. Di Luca, and A. Padovani Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease Neurosci. Lett. 343 2003 213 215
6. L.G. Costa, T.B. Cole, A. Vitalone, and C.E. Furlong Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity Clin. Chim. Acta 352 2005 37 47
7. S.A. Eagger, and R.J. Harvey Clinical heterogeneity: responders to cholinergic therapy Alzheimer Dis. Assoc. Disord. 9 Suppl. 2 1995 37 42
8. M.R. Farlow, D.K. Lahiri, J. Poirier, J. Davignon, L. Schneider, and S.L. Hui Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease Neurology 50 1998 669 677
9. M.R. Farlow, R. Lane, S. Kudaravalli, and Y. He Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers Pharmacogenom. J. 4 2004 332 335
10. G.S. Getz, and C.A. Reardon Paraoxonase, a cardioprotective enzyme: continuing issues Curr. Opin. Lipidol. 15 2004 261 267
11. R. Humbert, D.A. Adler, C.M. Disteche, C. Hassett, C.J. Omiecinski, and C.E. Furlong The molecular basis of the human serum paraoxonase activity polymorphism Nat. Genet. 3 1993 73 76
12. I. Kondo, and M. Yamamoto Genetic polymorphism of paraoxonase 1 (PON 1) and susceptibility to Parkinson's disease Brain Res. 806 1998 271 273
13. K.L. Lanctot, N. Herrmann, K.K. Yau, L.R. Khan, B.A. Liu, M.M. LouLou, and T.R. Einarson Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis C.M.A.J. 169 2003 557 564
14. J. Poirier, M.C. Delisle, R. Quirion, I. Aubert, M. Farlow, D. Lahiri, S. Hui, P. Bertrand, J. Nalbantoglu, B.M. Gilfix, and S. Gauthier Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease Proc. Natl. Acad. Sci. U.S.A. 92 1995 12260 12264
15. R. Pola, E. Gaetani, A. Flex, L. Gerardino, F. Aloi, R. Flore, M. Serricchio, P. Pola, and R. Bernabei Lack of association between Alzheimer's disease and Gln-Arg 192 Q/R polymorphism of the PON-1 gene in an Italian population Dement. Geriatr. Cogn. Disord. 15 2003 88 91
16. M.A. Raskind, E.R. Peskind, T. Wessel, and W. Yuan Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group Neurology 54 2000 2261 2268
17. A.S. Rigaud, L. Traykov, L. Caputo, M.C. Guelfi, F. Latour, R. Couderc, F. Moulin, J. De Rotrou, F. Forette, and F. Boller The apolipoprotein E epsilon4 allele and the response to tacrine in Alzheimer's disease Eur. J. Neurol. 7 2000 255 258
18. A.S. Rigaud, L. Traykov, F. Latour, R. Couderc, F. Moulin, and F. Forette Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease Pharmacogenetics 12 2002 415 420
19. L. Rodrigo, A.F. Hernandez, J.J. Lopez-Caballero, F. Gil, and A. Pla Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role Chem. Biol. Interact. 137 2001 123 137
20. J.B. Standbridge Pharmacotherapeutic approaches to the treatment of Alzheimer's disease Clin. Ther. 26 2004 615 630